The National Association of Statutory Health Insurance Funds (GKV), whose members insure 90% of the German population, have released data on reimbursed medical cannabis usage covering the entirety of 2020. The new data reveals that reimbursed sales of medical cannabis were worth €165 million in 2020.
The GKV have released data showing that the market for medical cannabis in Germany continued to grow in 2020, increasing by 34% compared to 2019 (excluding the newly added product Epidiolex). Sales reached a new record in Q4 albeit by a slim margin, totaling €43 million. This does not include the sales of cannabis which were paid for privately.
Dried flowers and flowers in preparation are the most important category of medicines in terms of sales.
As detailed in the recently released European Cannabis Report, we estimate Germany had 128,000 active patients at the end of 2020. Cannabis is now supplied to Germany from a wide range of countries including Canada, Netherlands, Uruguay, Israel and Australia. Domestically produced cannabis should be sent from producers to the BfArM within the first half of the year and be sold to patients before the end of 2021.
Statutory health insurance companies reject 38% of the applications for reimbursement from patients, limiting doctors ability to prescribe to their patients. This could be solved in the future by making the legislation around insurance of medical cannabis less ambiguous and making insurance of prescribed cannabis mandatory for statutory insurers.
Source: Prohibition Partners
VK PREMIUM offers an enhanced palette of advisory services to facilitate medical cannabis investments in Greece.
Call us at : +30 2106835560, send email to : info[@]vkmedicalcannabis.com or fill the bellow form: